Novartis Poised For Growth As It Expands Its Pharma Focus And Accelerates Pipeline
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The Swiss pharma expands its areas of focus in pharmaceuticals to include dedicated units within its pharma business for respiratory, dermatology, heart failure and cell therapy, as its oncologic products continue to advance – its CDK 4/6 inhibitor will enter Phase III this year.